pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CAR-T · news · pharmadog
← back to CAR-T
News · CAR-T
124
stories
25d
Tyra shares slip as bladder cancer responses fall short of investor expectations
biospace
25d
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
26d
STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
stat
26d
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
biospace
26d
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
biopharma dive
26d
STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals
stat
27d
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T
endpoints
27d
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
stat
27d
BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T
endpoints
27d
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
biopharma dive
27d
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
28d
BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer
fiercebiotech
Sep 5, 26
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
endpoints
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
stat
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Sep 3, 26
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
Sep 3, 26
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
Sep 2, 26
Novartis CAR-T deaths raise questions over acceptable autoimmune risk
endpoints
Sep 2, 26
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
biopharma dive
Sep 2, 26
Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapies
endpoints
Sep 2, 26
TScan axes 75% of workforce to make room for solid tumor programs
fiercebiotech
Sep 1, 26
Arsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-T
endpoints
Sep 1, 26
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
Sep 1, 26
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T
biospace
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Sep 1, 26
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
fiercebiotech
Sep 1, 26
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
endpoints
Sep 1, 26
Recon: Trump announces new pricing deals with midsize biotechs; Novartis pauses CAR-T trials after patient deaths
raps
← prev
page 2 of 5
next →
